Abstract
Twenty breast cancer patients from Magdalena V. de Martínez Hospital, Buenos Aires, selected by their higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB) were treated for 14 days with 200 mg mifepristone (MFP) p.o. before surgery (MIPRA; NCT02651844). A decrease in the proliferation index, greater than 30% was observed in 70% of the MFP-treated patients [primary endpoint (e.p.)]. RNA-Seq studies performed in 8 paired samples supported these findings and suggested that MFP increased tissue remodeling and immune-related pathways (secondary e.p.).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
